title: Reinventing bioinnovation.
abstract: The landscape for bioinnovation is undergoing a seismic shift as drug developers, regulators, academic institutions, and government research organizations adapt to the formidable challenge of bringing new medicines to market. The inability to translate current advances in the scientific understanding of disease into new therapeutics is forcing all sectors to replace traditional drug development paradigms with newer and more efficient models. This issue of Clinical Pharmacology & Therapeutics explores these changes to the bioinnovation ecosystem.
authors: K I
authors: KI
authors: Kaitin
authors: P K
authors: PK
authors: Honig
mesh_terms: D017277:Drug Approval; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D033161:Government Regulation; D062069:Inventions / Q000639:trends*; D055818:Public-Private Sector Partnerships; D014481:United States; D014486:United States Food and Drug Administration